Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer

British Journal of Cancer

Volumn 110, Issue 10, 2014, Pages 2506-2513

  Toyoda, M ^a   Kaira, K ^a,b   Ohshima, Y ^c   Ishioka, N S ^c   Shino, M ^a   Sakakura, K ^a   Takayasu, Y ^a   Takahashi, K ^a   Tominaga, H ^a   Oriuchi, N ^a   Nagamori, S ^d   Kanai, Y ^d   Oyama, T ^a   Chikamatsu, K ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GUNMA UNIVERSITY HOSPITAL   (Japan)

^c JAPAN ATOMIC ENERGY AGENCY   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSPORTER; AMINO ACID TRANSPORTER XCT; ANTINEOPLASTIC AGENT; ASC AMINO ACID TRANSPORTER 2; CD34 ANTIGEN; KI 67 ANTIGEN; L TYPE AMINO ACID TRANSPORTER 1; PROTEIN 4F2HC; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CAPILLARY DENSITY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; ORAL SURGERY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TONGUE CARCINOMA; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID TRANSPORT SYSTEM ASC; AMINO ACID TRANSPORT SYSTEM Y+; ANTIGENS, CD98 HEAVY CHAIN; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; OXONIC ACID; PROGNOSIS; TAXOIDS; TEGAFUR; TONGUE NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84900542750     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.178     Document Type: Article

References (29)

1. Altman A, Cardenas JM, Houghten RA, Dixon FJ, Theofilopoulos AN (1984) Antibodies of predetermined specificity against chemically synthesized peptides of human interleukin 2. Proc Natl Acad Sci 81: 2176-21 80.
2. Baek S, Choi CM, Ahn SH, Lee JW, Gong G, Ryu JS, Oh SJ, Bacher-Stier C, Fels L, Koglin N, Hultsch C, Schatz CA, Dinkelborg LM, Mittra ES, Gambhir SS, Moon DH (2012) Explor atory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L- glutamate for imaging xC-transporter using positron emission tomography in patients with non-small cell lung or breast cancer. Clin Cancer Res 18: 5427-5437.
3. Bello IO, Soini Y, Salo T (2010) Prognostic evaluation oral tongue cancer: Means, markers and perspectives (I). Oral Oncol 46: 630-635.
4. Chairoungdua A, Kanai Y, Matsuo H, Inatomi J, Kim DK, Endou H (20 01) Identification and characterization of a novel member of the heterodimeric amino acid transporter family presumed to be associated with an unknown heavy chain. J Biol Chem 276: 49390-49399.
5. Christensen HN (1990 ) Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 70: 43-77.
6. Fuch BC, Finger RE, Onan MC, Bode BP (2007) ASCT2 silencing regulates mammalian target of rap amycin growth and survival signaling in human hepatoma cells. Am J Physiol Cell Physiol 293: C55-C63.
7. Fuchs BC, Bode BP (2006) Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime Semin Cancer Biol 15: 254-266.
8. Furuya M, Horiguchi J, Nakajima H, Kanai Y, Oyama T (2012) Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci 103: 382-389.
9. Huang Y, Dai Z, Barbacioru C, Sadee W (2005) Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res 65: 7446-7454.
10. Ichin oe M, Mikami T, Yoshida T, Igawa I, Tsuruta T, Nakada N, Anzai N, Suzuki Y, Endou H, Okayasu I (2011) High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: Comparison with non-cancerous l esions. Pathol Int 61: 281-289.
11. Imai H, Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N, Ishizuka T, Nagamori S, Promchan K, Nakajima T, Yamamoto N, Mori M, Kanai Y (2010) Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Anticancer Res 30: 4819-4828.
12. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Tanaka S, Ishizuka T, Kanai Y, Endou H, Nakajima T, Mori M (2008) Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. B r J Cancer 98: 742-748.
13. Kaira K, Oriuchi N, Takahashi T, Nakagawa K, Ohde Y, Okumura T, Murakami H, Shukuya T, Kenmotsu H, Naito T, Kanai Y, Endo M, Kondo H, Nakajima T, Yam amoto N (2011) LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. Am J Transl Res 3: 468-478.
14. Kaira K, Sunose Y, Arakawa K, Ogawa T, Sunaga N, Shimizu K, Tominaga H, Oriuchi N, Itoh H, Nagamori S, Kanai Y, Segawa A, Furuya M, Mori M, Oyama T, Takeyoshi I (2012) Prognostic significance of L-type amino acid transporter 1 expression in surgically resec ted pancreatic cancer. Br J Cancer 107: 632-638.
15. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H (1998) Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol C hem 273: 23629-23632.
16. Khunweeraphong N, Nagamori S, Wiriyasermkul P, Nishinaka Y, Wongthai P, Ohgaki R, Tanaka H, Tominaga H, Sakurai H, Kanai Y (2012) L-glutamate enhances methylmercury toxicity by synergistically increasing oxidative stress. J Pharmacol Sci 119: 368-380.
17. Kim CS, Moon IS, Park JH, Shin WC, Chun HS, Lee SY, Kook JK, Kim HJ, Park JC, Endou H, Kanai Y, Lee BK, Kim do K (2010) Inhibition of L-type amino acid transporter modulates the expression of cell cycle regulatory factors in KB oral cancer cells. Biol Pharm Bull 33: 1117-1121.
18. Li R, Younes M, Frolov A , Wheeler TM, Scardino P, Ohori M, Ayala G (2003) Expression of neutral amino acid transporter ASCT2 in human prostate. Anticancer Res 23: 3413-3418.
19. Liu XM Reyna SV Ensenat D Peyton KJ Wang H Schafer AI Durante W 2004 Platelet-derived growth factor stimulates LAT1 gene expression in vascular smooth muscle: Role in cell growth FASEB J 18 768-770.
20. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, Yang H, Hild M, Kung C, Wilson C, Myer VE, MacKeigan JP, Porter JA, Wang YK, Cantley LC, Finan PM, Murphy LO (2009) Bidirectional transport of a mino acids regulates mTOR and autophagy. Cell 136: 521-534.
21. Nobusawa A, Kim M, Kaira K, Miyashita G, Negishi A, Oriuchi N, Higuchi T, Tsushima Y, Kanai Y, Yokoo S, Oyama T (2013) Diagnostic usefulness of 18F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma. Eur J Nucl Med Mol Imaging 40(11): 1692-1700.
22. Oppedisano F, Catto M, Koutentis PA, Nicolotti O, Pochini L, Koyioni M, Introcaso A, Michaelidou SS, Carotti A, Indiveri C (2012) Inactivation of the glutamine/amino acid transporter ASCT2 by 1,2,3-dithiazoles: Proteoliposomes as a tool to gain insights in the molecular mechanism of action and of antitumor activity. Toxicol Appl Pharmacol 93: 93-102.
23. Regezi JA, Sciubba JJ, Jordan RCK (2008) Oral Pathology: Clinical, Pathologic Correlation, 5th edn. Saunders Elsevier: St Louis, USA.
24. Sakata T, Ferdous G, Tsuruta T, Satoh T, Baba S, Muto T, Ueno A, Kanai Y, Endou H, Okayasu I (2009) L-type amino acid transporter 1 as a novel biomarker for high-grad e malignancy in prostate cancer. Pathol Int 59: 7-18.
25. Takeuchi S, Wada K, Toyooka T, Shinomiya N, Shimazaki H, Nakanishi K, Nagatani K, Otani N, Osada H, Uozumi Y, Matsuo H, Nawas hiro H (2013) Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas. Neurosurgery 72: 33-41.
26. Whitte D, Ali N, Carlson N, Younes M (2002) Overexpression of the neutral amino acid transporter ASCT2 in human colorectal adenocarcinoma. Anticancer Res 22: 2555-2557.
27. Xu D, Hemler ME (2005) Metabolic activation-related CD147-CD98 complex. Mol Cell Proteomics 4: 1061-1071.
28. Yamauchi K, Sakurai H, Kimura T, Wiriyasermkul P, Nagamori S, Kanai Y, Kohno N (2009) System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and nec k squamous cell carcinoma cell line. Cancer Lett 276: 95-101.
29. Yanagida O, Kanai Y, Chairoungdua A , Kim DK, Segawa H, Nii T, Cha SH, Matsuo H, Fukushima J, Fukasawa Y, Tani Y, Taketani Y, Uchino H, Kim JY, Inatomi J, Okayasu I, Miyamoto K, Takeda E, Goya T, Endou H (2001) Hum an L-type amino-acid transporter 1 (LAT 1): Characterization of function and expression in tumor cell lines. Biochim Biophys Acta 1514: 291-302.